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Abstract
Background: Chromodomain-helicase DNA binding protein 5 (CHD5) is an important tumor suppressor gene
deleted from 1p36.31 in neuroblastomas (NBs). High CHD5 expression is associated with a favorable prognosis,
but deletion or low expression is frequent in high-risk tumors. We explored the role of CHD5 expression in the
neuronal differentiation of NB cell lines.
Methods: NB cell lines SH-SY5Y (SY5Y), NGP, SK-N-DZ, IMR5, LAN5, SK-N-FI, NB69 and SH-EP were treated with
1–10 μM 13-cis-retinoic acid (13cRA) for 3–12 days. qRT-PCR and Western blot analyses were performed to measure
mRNA and protein expression levels, respectively. Morphological differences were examined by both phase contrast
and immunofluorescence studies.
Results: Treatment of SY5Y cells with 13cRA caused upregulation of CHD5 expression in a time- and dose-dependent
manner (1, 5, or 10 μM for 7 or 12 days) and also induced neuronal differentiation. Furthermore, both NGP and SK-N-DZ
cells showed CHD5 upregulation and neuronal differentiation after 13cRA treatment. In contrast, 13cRA treatment of
IMR5, LAN5, or SK-N-FI induced neither CHD5 expression nor neuronal differentiation. NB69 cells showed two different
morphologies (neuronal and substrate adherent) after 12 days treatment with 10 μM of 13cRA. CHD5 expression
was high in the neuronal cells, but low/absent in the flat, substrate adherent cells. Finally, NGF treatment caused
upregulation of CHD5 expression and neuronal differentiation in SY5Y cells transfected to express TrkA (SY5Y-TrkA) but
not in TrkA-null parental SY5Y cells, and both changes were blocked by a pan-TRK inhibitor.
Conclusions: Treatment with 13cRA induces neuronal differentiation only in NB cells that upregulate CHD5. In addition,
NGF induced CHD5 upregulation and neuronal differentiation only in TrkA expressing cells. Together, these results
suggest that CHD5 is downstream of TrkA, and CHD5 expression may be crucial for neuronal differentiation induced
by either 13cRA or TrkA/NGF signaling.
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Background
Deletion of 1p36 is one of the most common genetic
changes in neuroblastomas (NBs), and 1p deletion is
strongly associated with MYCN amplification, advanced
stages of disease and a poor prognosis [1]. Deletion of
1p36 is also found in many other malignancies, includ-
ing adult cancers, and its loss is also associated with a
poor prognosis in these tumors [2–5]. One or more tumor
suppressor genes (TSGs) presumably reside in this deleted
region. We narrowed the smallest region of deletion (SRD)
in over 1,200 NBs to a <2 Mb region of 1p36.31, and we
identified the gene encoding chromodomain-helicase-DNA
binding protein 5 (CHD5) as the most likely TSG deleted
in this region [6–8].
CHD5 is the fifth member of the nine-member CHD
family, and it is most homologous to CHD3 and CHD4,
which form a NuRD-type chromatin-remodeling com-
plex [9–11]. CHD3 and CHD4 are expressed ubiquitously,
but high CHD5 expression is restricted to the nervous
system and testis, suggesting that CHD5 has a role in
regulating the development of these tissues [7, 9, 12, 13].
There are reports that CHD5 acts as a TSG in other
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cancers, such as breast, colon, lung prostate, ovary and
others [10, 14–25]. Previously, we reported that high
CHD5 expression was correlated with favorable outcome
in NBs, whereas expression was low or absent in high-risk
NBs [6, 26]. We also reported that the promoter of CHD5
is frequently methylated in NBs with low or absent CHD5
expression [6, 26], and suppression of CHD5 expression
by promoter methylation has been found in other cancers
as well [18, 21, 22, 27]. CHD5 expression can suppress the
growth of many types of cancers, which suggests it is an
important TSG in many forms of neoplasia [10]. CHD5
expression in the testis is responsible for the histone to
protamine switch in spermatogenesis [12, 28, 29]. How-
ever, the function of CHD5 in neuronal cells and other
tissues is unknown.
NBs are derived from sympathoadrenal precursors,
and several pathways have been implicated in the
neuronal differentiation of these cells, including nerve
growth factor (NGF) and its cognate receptor TrkA.
TrkA-expressing sympathetic neurons from newborn
animals differentiate in vitro in the presence of NGF
but undergo apoptosis in its absence [30]. Similarly,
TrkA-expressing NB cells differentiate and survive for
months when grown in vitro with NGF, but they also
undergo apoptosis and die within a week without NGF
[31]. Retinoids have also been shown to induce neur-
onal differentiation in NB cells in culture [32–34].
However, it is unclear if retinoids act directly through
retinoic acid receptors, or indirectly by regulating the
expression of other genes and proteins.
In this study, we showed that treatment of NB cells
with 13-cis retinoic acid (13cRA) caused increased
CHD5 expression, which was consistently associated
with neuronal differentiation. 13cRA induces gene ex-
pression changes as well as morphological differentiation
based on the cell type. Our analysis also showed a direct
correlation between CHD5 expression and neuronal dif-
ferentiation involving TrkA signaling, induced by NGF
treatment in NB cells. Our results strongly suggest that
CHD5 expression plays an important role in neuronal
differentiation induced by both 13cRA and NGF/TrkA
signaling.
Results
Neuronal differentiation and upregulation of CHD5
Expression by 13cRA
To determine if there were changes in CHD5 expression
in response to 13cRA treatment, we treated SY5Y cells
(a neuronal subclone of SK-N-SH) with 1 μM, 5 μM or
10 μM 13cRA for 7 or 12 days and observed cells
directly under the microscope. During the course of
treatment, cells showed clear neurite extension in re-
sponse to 13cRA (Fig. 1a). Representative phase contrast
images were chosen to measure neurite outgrowth in
the presence or absence of retinoic acid after 6 and
10 days (Additional file 1: Figure S1A). Neurite out-
growth was significantly longer in RA-treated SY5Y
cultures compared to untreated controls (Additional
file 1: Figure S1B). We also noticed a reduction in NB
cell number upon retinoic acid treatment. These ob-
servations were confirmed by sulphorhodamine B
(SRB) calorimetric assays in SY5Y, and also in the NB69
cell line (Additional file 2: Figure S2). To further validate
neuronal differentiation in NB cells in response to 13cRA
treatment, we performed immunofluorescence of SY5Y
cells with neuronal markers: tyrosine hydroxylase
(TH), synaptophysin (SYP) and βIII-Tubulin, in addition
to the observations made through phase contrast mi-
croscopy. Cells treated with 13cRA showed clear in-
creased expression for all the tested neuronal markers,
whereas control cells showed limited or no expression
(Fig. 1b). These results clearly show that 13cRA induced
morphological and biochemical neuronal differentiation
in SY5Y cells.
In addition, to assess the effects of 13cRA treatment
on CHD5 expression, we performed western blot ana-
lyses. Immunoblotting of nuclear proteins for CHD5
showed dramatic upregulation of CHD5 by 13cRA in
both a time- and dose- dependent manner. Blots were
stripped and reprobed with HDAC2 as an internal con-
trol for nuclear protein (Fig. 2a). In order to confirm the
association of increased CHD5 expression with neuronal
differentiation, we extended our studies to additional NB
cell lines. In addition to SY5Y, we treated NB cell lines
NGP, SK-N-DZ, IMR5, LAN5, SK-N-FI, NB69 and SH-
EP with 10 μM 13cRA for 12 days. Both SK-N-DZ and
LAN5 cells showed cellular toxicity after a few days of
10 μM 13cRA treatment, so the dose was reduced to
5 μM 13cRA, and we treated both lines for only 3 days.
We analyzed CHD5 protein expression in NB cells
with or without 13cRA treatment by western blot ana-
lysis. Immunoblotting results are shown from three
representative lines that responded to 13cRA exposure
by undergoing neuronal differentiation (SY5Y, NGP,
SK-N-DZ), and three that did not (IMR5, LAN5, SK-
N-FI). Similar to SY5Y cells, NGP and SK-N-DZ cells
showed clear upregulation of CHD5 protein by 13cRA
treatment (Fig. 2b). However, IMR5, LAN5 and SK-N-
FI cells showed no significant difference in CHD5
protein expression in response to 13cRA treatment
(Fig. 2c), and no neuronal differentiation was observed
(Table 1). We also treated SH-EP cells, a substrate-
adherent (S-type) subclone of SK-N-SH, with 13cRA,
but there was no appreciable change in either CHD5
expression or morphology (Table 1). These results
suggest that increased CHD5 expression may be re-
quired for neuronal differentiation in response to
13cRA treatment.
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Neuronal differentiation of NB69 cells by 13cRA
Interestingly, the NB69 cell line showed a unique re-
sponse to the 13cRA treatment. Unexposed NB69 cells
exhibited a round, tightly clustered and semi-adherent
phenotype (Additional file 3: Figure S3a). Treatment
with 10 μM 13cRA induced a change in morphology
after 1 day. However, after 7 days of treatment, there
were two very different morphologic populations of
cells—a smaller population of cells with a neuronal
morphology and neurite outgrowth, and a larger popula-
tion that were flat and substrate adherent (Additional
file 3: Figure S3a). In order to further explore neuronal
differentiation in NB cells upon 13cRA treatment, we





























Fig. 1 Neuronal differentiation of SY5Y cells with 13cRA treatment. (a) Representative phase contrast images showing SY5Y cell morphology
change with or without 13cRA treatment (10 μM, 12 days). Multiple long neurites were observed in the presence of 13cRA. (b) Immunofluorescence of
SY5Y cells with or without 13cRA treatment. Representative immunofluorescence images obtained when cells were treated with 13cRA and stained with
neuronal markers tyrosine hydroxylase (TH), synaptophysin (SYP), and βIII-Tubulin. Control cells did not show significant staining with TH or SYP, but there
was some βIII-Tubulin staining
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neuronal markers—TH, SYP and βIII-Tubulin—before
and after 13cRA treatment. Cells treated with 13cRA
showed neurite outgrowth and increased expression of
neuronal markers exclusively in the neuronal cells
(Additional file 3: Figure S3b). Additional morphological
and biochemical evidence of neuronal differentiation in
the neuronal subtype are also shown (Additional file 2:
Figure S2 and Additional file 4: Figure S4). These results
further suggest an association between CHD5 upregula-
tion and neuronal differentiation in response to 13cRA
in NB cells.
Relationship between CHD5 and TrkA expression
To further investigate the relationship between CHD5
expression and neuronal differentiation, we analyzed the
expression patterns of CHD5 and TrkA in our panel of
NB lines (SY5Y, NGP, SK-N-DZ, IMR5, LAN5, and SK-
N-FI) with or without 13cRA treatment (Fig. 3). Upregu-
lation of both CHD5 and TrkA were found in the same
cell lines that showed neuronal differentiation. SY5Y
cells showed a significant increase over baseline expres-
sion for both TrkA and CHD5 in response to 13cRA
(Fig. 3a). Similar, significant increases in TrkA and
CHD5 expression were observed in NGP and SK-N-DZ
in response to 13cRA with NGP (Fig. 3b, c). The other
cell lines—IMR5, LAN5, and SK-N-FI—did not show
significant changes in either CHD5 or TrkA gene ex-
pression with 13cRA treatment and did not differentiate
(Fig. 3d, e, f ). These results suggest that upregulation of
both CHD5 and TrkA expression was required for cells
to undergo morphological differentiation in response to
13cRA treatment.
Increased CHD5 Expression by NGF-induced Activation of
TrkA
To analyze the association between the NGF-TrkA sig-
naling pathway and CHD5 expression, we treated SY5Y
and SY5Y-TrkA cells with NGF, the cognate ligand of
TrkA. Cells were harvested after 2, 4 and 6 days of NGF
treatment, and CHD5 expression was analyzed by qPCR
and western blot. Before NGF treatment, SY5Y-TrkA
cells showed about 2.5 fold higher expression of CHD5
compared to the parental SY5Y cell line. Treatment with
NGF (50 ng/ml) induced neuronal differentiation and
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Fig. 2 Upregulation of CHD5 expression in NB cells treated with
13cRA. (a) Representative immunoblot showing the upregulation
of CHD5 from nuclear extracts of SY5Y cells treated with 13cRA at
different concentrations and times. Western blot was stripped
and probed with HDAC2 as an internal control for nuclear
proteins, and we observed uniform HDAC2 expression. (b) and (c)
Immunoblotting of CHD5. NB cell lines SY5Y, NGP, SK-N-DZ, IMR5,
LAN5 and SK-N-FI were treated in the presence or absence of
10 μM 13cRA for 12 days and nuclear proteins were extracted.
Western analysis showed CHD5 protein upregulation in SY5Y,
NGP and SK-N-DZ cells (b), but not in IMR5, LAN5 and SK-N-FI (c).
HDAC2 protein was used as an internal control for these blots








CHD5 expression (WB or Q-PCR) TrkA expression (Q-PCR) Observed cell morphology changea
Pre-RA RA+ RA+
SY5Y No del NA + ↑ ↑ Neuronal differentiation
NGP Trans A - ↑ ↑ Neuronal differentiation
SK-N-DZ No del A - ↑ ↑ Differentiation/death
IMR5 Del A - → → No obvious change
LAN5 Del A - → → Cell death
SK-N-FI No del NA - → → No obvious change
NB69 Del NA + ↓ ND N- and S-type cells after RA treatment
SH-EP No del NA - → ND S-type. No obvious change
Del Deleted, No del Not deleted, Trans Translocated, A Amplified, NA Not amplified, RA Retinoic acid, ND Not done
aAll cells were N-type and remained so except for SH-EP (S-type) and NB69 after RA treatment
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dependent manner in SY5Y-TrkA cells, whereas the par-
ental SY5Y cells did not show any change in morphology
or CHD5 expression in response to NGF (Fig. 4a).
Similar results in were obtained in both lines with
CHD5 protein expression upon retinoic acid treatment
(Fig. 4b). Densitometric analysis of representative CHD5
protein expression data are presented as supplementary
data (Fig. 4c).
To confirm that CHD5 upregulation by 13cRA was a
result of the activation of TrkA, we used CEP701 (les-
taurtinib), a potent TrkA inhibitor, to block the upregu-
lation of TrkA expression by 13cRA in SY5Y-TrkA cells
(Fig. 5). Cells were treated with 13cRA for 4 days, and
then 50 nM or 100 nM of CEP701 were added to the
medium with 13cRA for an additional day. Our results
indicate that the CHD5 expression was upregulated after
5 days of 13cRA treatment, but the expression was
suppressed in a dose-dependent manner by CEP701
treatment (Fig. 5a), with a corresponding inhibition of
neuronal differentiation, as demonstrated by a decrease
in neurite extension (Additional file 5: Figure S5). In
addition to inhibition of neuronal differentiation we also
noticed some growth inhibition or cell death at 100 nM
CEP-701 concentrations that is known to block TrkA
signaling and induce cell death. Similar results were ob-
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Fig. 3 TrkA and CHD5 expression in NB cell lines. NB cell lines were treated with 5 or 10 μM of 13cRA for 3, or 12 days as indicated. CHD5 and
TrkA was upregulated in (a) SY5Y, (b) NGP and (c) SK-N-DZ cell lines whereas (d) IMR5, (e) LAN5, and (f) SK-N-FI cells did not show a significant
change in either CHD5 or TrkA gene expression upon with 13cRA treatment. Values were normalized (GAPDH) and calculated as relative levels
of CHD5 and TrkA expression in untreated samples. The graphs show the results of at least three independent experiments in triplicates (SD).
Statistical analysis was performed using one-way ANOVA using Prism followed by Tukey’s post-test and P-values were reported as shown.
ns = not significant
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treatment (Fig. 5b). Densitometric analysis of representa-
tive CHD5 protein expression data was presented to
indicate the difference in CHD5 expression between
control, 13cRA and CEP-701 treatments (Fig. 5c). These
results suggest that CHD5 expression is regulated down-
stream of NGF-TrkA signaling cascade.
Discussion
In this study, we observed neuronal differentiation of
NB cell lines in response to 13cRA, which was associ-
ated with upregulation of TrkA and CHD5 (Table 1).
13cRA is well studied as a model for inducing neuronal
differentiation in some NB cell lines, and it has also been
used in clinical treatment of high-risk NB [33, 35, 36].
However, not all NB cells show neuronal differentiation
in response to 13cRA, and the mechanisms regulating
13cRA responsiveness are not understood. Ross and col-
leagues [37] classified NB cell morphology into three
types; N-type for neuroblastic precursors, S-type for
non-neuronal, substrate-adherent Schwannian precur-
sors, and I-type for intermediate between N- and S-type.
They also stated that N-type and I-type cells show a
differentiation response to the 13cRA treatment, but S-
type cells do not [38]. Our studies show that CHD5
expression is found in N-type cells (and not S-type cells,
as seen in the NB69 or SH-EP line), and CHD5 expres-
sion is enhanced markedly by 13cRA treatment in N-
type cells, concurrent with the neuronal differentiation.
However, some cell lines, especially those with 1p
deletion, do not undergo neuronal differentiation in
response to 13cRA, and CHD5 expression is usually very
low or absent in these cells.
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Fig. 4 Effect of NGF on CHD5 expression. (a) CHD5 expression in SY5Y and SY5Y-TrkA cells with or without NGF (50 ng/ml) treatment. The values
for CHD5 expression were calculated relative to the level of CHD5 expression in SY5Y on day 2 without NGF treatment. The graph shows the
results of three independent experiments (SD). Statistical analysis was performed using two-way ANOVA using Prism followed by a Sidak post-test
and P values were reported as shown. ns = not significant. (b) Protein expression of CHD5 and HDAC2. (c) Densitometric analysis of CHD5 protein
expression in SY5Y-TrkA cells. The number of pixels from each band obtained from a representative Western blot were measured, and a bar graph
was created using Prism to indicate the difference in CHD5 expression in the control and NGF treated cultures
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Retinoids like 13cRA exert their function through the
retinoic acid receptors, RAR and RXR. In the presence
of 13cRA, RXR and RAR form dimers and bind to a
DNA retinoic acid response element (RARE) [33, 35,
39]. The typical RARE sequence consists of two PuG(G/
T)TCA motifs separated by a several nucleotides [39].
CHD5 has several partial RARE elements in the
promoter sequence, but they are not the complete.
Balmer and colleagues [40] classified RA-responsive
genes into direct or indirect response groups. They
defined direct regulation by RA as gene response
(increase in expression) within 6 h of treatment with
1 μM RA, and the directly regulated genes had a typ-
ical RARE in its promoter. CHD5 does not fit in these
criteria, since the response to 13cRA is longer than
1 day and it requires a higher dose of 13cRA for this
response. This suggests that activation of CHD5 in-
duced by 13cRA is an indirect response, although ne-
cessary for neuronal differentiation.
NB69 cells showed an interesting response to the
13cRA treatment. Cells showed two different types of
morphology after 13cRA treatment, one is N-type and
B
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Fig. 5 Effect of the TRK inhibitor CEP-701 on RA induced CHD5 expression. (a) CHD5 expression in SY-5Y-TrkA cells with or without RA and in the
presence or absence of CEP-701. The values for CEP-701 inhibition were calculated relative to the levels of CHD5 expression upon 13cRA treatment. The
graph shows the results of three independent experiments. Statistical analysis was performed using one-way ANOVA using Prism followed by Tukey’s
post-test and P-values were reported as shown. (b) Protein expression of CHD5 and HDAC2. (c) Densitometric analysis of CHD5 protein expression in
SY5Y-TrkA cells. The number of pixels from each band obtained from a representative Western blot were measured, and a bar graph was created using
Prism to indicate the difference in CHD5 expression between control, 13cRA and CEP-701 treatments
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the other is S-type. CHD5 expression was high only in
neuronal N-type cells, but very low in substrate-
adherent S-type cells. Similar heterogeneity of cell
morphology was found in the parental SK-N-SH NB
cell line that had two different types of cells. The N-
type was subcloned as the SH-SY5Y cell line, and S-
type subcloned as the SH-EP cell line. Indeed, we saw
neuronal differentiation in response to 13cRA only in
SY5Y cells and not in SH-EP cells (Table 1), support-
ing the hypothesis that CHD5 expression is important
for neuronal differentiation.
TrkA is also important for the neuronal differentiation
of NB cells. In response to its cognate ligand NGF, TrkA
induces neuronal differentiation in NBs [41, 42]. TrkA is
also upregulated by 13cRA in some NB cell lines, but
not in others, and this pattern correlated with the induc-
tion of CHD5 expression and with neuronal differenti-
ation. We found marked TrkA upregulation following
13cRA treatment only in SY5Y, NGP and SK-N-DZ, the
lines in which CHD5 expression was also markedly in-
creased and that underwent neuronal differentiation.
However, three other lines (IMR5, LAN5, SK-N-FI)
showed neither CHD5 upregulation nor neuronal differ-
entiation in response to 13cRA.
Previously, we had transfected CHD5 into several
neuroblastoma lines (e.g., NLF, IMR5) [6], and although
there was dramatic inhibition of growth, clonigenicity
and tumorigenicity, we did not see any substantial mor-
phological change or neuronal differentiation in these
lines. Both IMR5 (shown here) and NLF (data not
shown) are unresponsive to 13cRA, and the presence of
increased levels of exogenous CHD5 alone did not pro-
duce neuronal differentiation in these lines. Taken to-
gether with our current results, this suggests that CHD5
expression may necessary but not sufficient to induce
neuronal differentiation, as 13cRA likely has other ef-
fects in addition to upregulation of TrkA and CHD5
expression.
The role of CHD5 in neuronal differentiation of NB
cells needs further investigation. Egan et al. reported a
role of CHD5 in neurogenesis, and they showed that
CHD5 directly interacts with trimethylated H3K27,
regulating the expression of genes that are important for
neuronal differentiation [13]. Considering the likely role
of CHD5 as a component of a NuRD complex [10, 11,
43, 44] it could regulate neuronal differentiation by
suppressing the expression of growth-related genes or
inducing the expression of differentiation-related genes.
Potts et al. have also shown the importance of CHD5
expression in neurons, and its depletion is linked to
Alzheimer’s disease [43]. In addition, CHD5 expression
is induced specifically in neuronal progenitors, indicat-
ing a role for neuronal differentiation and maturation,
based on its expression patterns [45]. Thus, there is
growing evidence that CHD5 has an important role in
the regulation of neuronal differentiation, as well as in
tumor suppression.
Conclusions
Overall, our results suggest that CHD5 expression and
TrkA expression are both downstream of the pathway of
gene activation and neuronal differentiation induced by
13cRA. CHD5 gene expression is also upregulated by
NGF in TrkA-transfected SY5Y cells, but not in TrkA-
null parental SY5Y cells. Although it is not clear if the
NGF-TrkA pathway is the main mechanism of CHD5
regulation, our data suggest that CHD5 is upregulated
downstream of the NGF-TrkA pathway.
Materials and methods
Cell lines and treatment with 13cRA and NGF
NB cell lines SH-SY5Y (SY5Y), NGP, SK-N-DZ, IMR5,
LAN5, SK-N-FI, NB69 and SH-EP were cultured in
RPMI 1640 medium with 10 % FBS at 37 °C, and 5 %
CO2. For the 13cRA treatment of cells, 13cRA (Sigma-
Aldrich, St. Louis, MO) was added to the medium at
different concentrations, and the medium was changed
daily. Also, we previously established an SY5Y clone
(SY5Y-TrkA) that constitutively expresses TrkA [46]. For
NGF treatment of cells, hNGF (PeproTech, Rocky Hill,
NJ) was added to the medium at the concentration of
50 ng/ml, and the medium was changed every two days.
For the analysis of TrkA inhibition, CEP701 (lestaurtinib,
Cephalon Inc. Frazer, PA) was added to the culture
medium.
Immunoblotting
Cells were harvested with 0.05 % trypsin after incubation
in each condition. Protein was extracted using NE-PER®
Nuclear and Cytoplasmic Extraction Reagents (Thermo–
Fisher Scientific; Pittsburgh, PA). SDS-PAGE and transfer
were performed with Invitrogen systems (Invitrogen–Life
Technologies; Grand Island, NY). Immunoblotting was
performed with the following primary and secondary anti-
bodies and dilutions: anti-CHD5 antibody (Santa-Cruz, sc-
68390; Santa Cruz Biotechnology, Inc.; Dallas, TX) 1:1000,
anti-HDAC2 antibody (Santa-Cruz, sc-6296) 1:1000, ECL-
donkey anti-rabbit IgG-HRP (GE NA934V; GE Healthcare
Life Sciences; Pittsburgh, PA) 1:2500, donkey anti-goat
IgG-HRP (Santa-Cruz, sc-2020) 1:5000. For each blot, the
reaction was performed at 4 °C overnight for the primary
antibody and at room temperature for 2 h for the secondary
antibody.
Real-time quantitative RT-PCR (Q-PCR)
The SYBR green system with SYBR® Green PCR Master
Mix (Applied Biosystems; Grand Island, NY) was used
for analysis of gene expression by qPCR. Primer sets for
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CHD5 TrkA/NTRK1 and GAPDH are shown in Additional
file 6: Table S1. All samples were run triplicate, and each
experiment was conducted at least 3 times. Values were cal-
culated as relative rates from a standard curve, and
GAPDH was used as an internal control. PCR was run on a
7900HT Fast Real-Time PCR System (Applied Biosystems,
Grand Island, NY).
Immunofluorescence
Cells were fixed on either 8-well chamber slides or 24-
well culture plates with 4 % formaldehyde. Blocking was
performed in PBS buffer with 0.1 % Triton X-100, 1 %
BSA and 10 % FBS for 2 h. Primary and secondary
antibody binding was performed in PBS with 0.5 % Tri-
ton X-100, 1 % BSA with the following concentrations:
CHD5 (Santa-Cruz sc-68390) 1:500; Tyrosine Hydroxy-
lase (Novocastra NCL-TH) 1:200; Synaptophysin (R&D
Systems Inc.) 1:500; βIII-Tubulin (R&D Systems Inc.)
1:500; anti-mouse secondary antibody (Invitrogen Alexa
Fluor 546) 1:500. Antibody binding was performed at
4 °C overnight with primary antibody and at room
temperature for 2 h with secondary antibody. Prolong
Gold Anti-fade reagent (Invitrogen, Palo Alto, CA)
was used for DAPI staining to preserve fluorescence
signal.
Sulphorhodamine B (SRB) assay
Sulforhodamine B (SRB) assays were performed to deter-
mine the effect of 13cRA on NB cells. SY5Y and NB69
cells (5×103/ well) in triplicates were plated in 96 well
plates and treated with or without 10 μM 13cRA. Plates
were harvested after 2, 5, and 7 days of 13cRA treatment
and processed for SRB assays as per the standard proto-
col. Cell viability was analyzed by SRB assay by measur-
ing optical density (OD) of bound dye. All experiments
were performed in triplicate and repeated at least 3
times.
Statistical analysis
Statistical analyses were performed using the Prism
ANOVA method. One-way ANOVA was performed
followed by Tukey’s post-test and two-way ANOVA
followed by a Sidak post-test. Each experiment was
performed at least three times and triplicate readings
were used and reported all p-values. For all the CHD5
expression analysis with or without retinoic acid, NGF
response and CEP-701 treatments values were com-
pared between untreated and treated samples.
Additional files
Additional file 1: Figure S1. (A) Neurite formation in SY5Y cells in
response to 13cRA. Representative phase contrast images depicting
extension of neurites in response to 13cRA treatment after 6 days and
10 days. Long neurites were observed when cells were treated with
13cRA. (B) Statistical analysis of neurite outgrowth following 13cRA
treatment in SY5Y cells. Length of neurites from three to five
representative fields of 13cRA treated cells were measured in μm and
compared with neurites from untreated cells. Neurites were measured
(μm-micrometer) from at least three independent experiments, and
p-values were calculated by one-way ANOVA using Prism followed by
Tukey’s post-test. (DOC 208 kb)
Additional file 2: Figure S2. Effect of 13cRA on cell proliferation by
SRB assay. SY5Y and NB69 cells were plated on 96 well plates and treated
with or without 10 μM retinoic acid. Plates were harvested after 2, 5, and
7 days of 13cRA treatment. Cell viability was analyzed by an SRB assay
measuring optical density (OD). Cell lines treated with 13cRA showed
lower OD, indicating reduced cell number compared to untreated
control cells. (DOC 46 kb)
Additional file 3: Figure S3. NB69 morphology in response to 13cRA.
(A) (A) Representative phase contrast images showing NB69 morphology
change with or without 13cRA treatment (10 μM, 12 days). Two very
different morphologic populations of cells were observed: a neuronal
morphology with neurite outgrowth (N-type) (Red arrows), and flat and
substrate adherent (S-type) (Blue arrows). (B) Immunofluorescence of NB69
cells with or without 13cRA treatment. Representative immunofluorescence
images obtained when cells were treated with 13cRA and stained with
neuronal markers TH, SYN, and βIII-Tubulin. (DOC 395 kb)
Additional file 4: Figure S4 (A) Detection of neurites in NB69 cells in
response to retinoic acid. Representative phase contrast images of NB69
cells showing long neurites upon 13cRA treatment for 6 and 10 days. (B)
Statistical analysis of various neurites upon 13cRA treatment in NB69 cells.
Length of neurites from various selected fields were measured in μm and
compared with neurites from untreated cells. Neurites were measured
(μm-micrometer) from at least three independent experiments and
p-values were calculated by one-way ANOVA using Prism followed by
Tukey’s post-test. (DOC 296 kb)
Additional file 5: Figure S5. (A) Neurite inhibition by CEP-701 in
SY5Y-TrkA cells. Representative phase contrast images of SY5Y-TrkA
cells depicting extension of neurites in response to 13cRA treatment
after 4 days, and subsequent neurite inhibition following 100 nM
CEP-701 treatment (μm-micrometer) (B) Statistical analysis of neurite
outgrowth following 13cRA as well as CEP-701 treatment of SY5Y-TrkA cells.
Length of neurites (μm-micrometer) from three to five representative fields
of 13cRA and CEP-701 treated cells were measured in μm and compared
with neurites from untreated cells. P-values were calculated by one-way
ANOVA using Prism followed by Tukey’s post-test. (DOC 148 kb)
Additional file 6: Table S1. Nucleotide sequences of primers used in
this study (DOCX 15 kb)
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